Story perspectives

Breakthrough Prize for Diabetes Research Amid Coverage Controversy

4/7/2025

30 4

Summary

Drucker Awarded Breakthrough

Dr. Daniel Drucker, a pioneering Canadian researcher, has been awarded the prestigious 2025 Breakthrough Prize for his groundbreaking work on the GLP-1 hormone, vital for diabetes and obesity treatments such as Ozempic. In a contrasting move, the Centers for Medicare and Medicaid Services have chosen not to cover weight-loss medications like Wegovy and Zepbound, leaving 7.5 million beneficiaries without access to these potentially life-changing drugs.

Summary

GLP-1 Drugs Reduce Dementia

Groundbreaking research reveals that GLP-1 drugs like Ozempic and Wegovy could slash dementia risk by 33% for those battling Type 2 diabetes. This promising finding has experts calling for more trials to uncover the full potential of these medications in safeguarding cognitive health and offering neuroprotective benefits.

1 of 2

Drucker Awarded Breakthrough

Dr. Daniel Drucker, a pioneering Canadian researcher, has been awarded the prestigious 2025 Breakthrough Prize for his groundbreaking work on the GLP-1 hormone, vital for diabetes and obesity treatments such as Ozempic. In a contrasting move, the Centers for Medicare and Medicaid Services have chosen not to cover weight-loss medications like Wegovy and Zepbound, leaving 7.5 million beneficiaries without access to these potentially life-changing drugs.

1 / 2